cancers Article Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid 1, 1, 1 2 1 Valeria Pecce y , Antonella Verrienti y, Luana Abballe , Raffaella Carletti , Giorgio Grani , Rosa Falcone 1, Valeria Ramundo 1, Cosimo Durante 1, Cira Di Gioia 2 , Diego Russo 3 , Sebastiano Filetti 1 and Marialuisa Sponziello 1,* 1 Department of Translational and Precision Medicine, “Sapienza” University of Rome, 00161 Rome, Italy;
[email protected] (V.P.);
[email protected] (A.V.);
[email protected] (L.A.);
[email protected] (G.G.);
[email protected] (R.F.);
[email protected] (V.R.);
[email protected] (C.D.); sebastiano.fi
[email protected] (S.F.) 2 Department of Radiological, Oncological and Pathological Sciences, “Sapienza” University of Rome, 00161 Rome, Italy; raff
[email protected] (R.C.);
[email protected] (C.D.G.) 3 Department of Health Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy;
[email protected] * Correspondence:
[email protected] These authors contributed equally to this work. y Received: 23 June 2020; Accepted: 11 July 2020; Published: 14 July 2020 Abstract: Hürthle cell carcinomas (HCC) are rare differentiated thyroid cancers that display low avidity for radioactive iodine and respond poorly to kinase inhibitors. Here, using next-generation sequencing, we analyzed the mutational status of primary tissue and poorly differentiated metastatic tissue from two HCC patients. In both cases, metastatic tissues harbored a mutation of SETD2, each resulting in loss of the SRI and WW domains of SETD2, a methyltransferase that trimethylates H3K36 (H3K36me3) and also interacts with p53 to promote its stability.